[h2]MS drug lifts GW Pharma[/h2]
By Neil Hume and Bryce Elder
Published: March 12 2009 02:00
GW pharmaceuticals rose 50 per cent to 59¾p on the back of clinical trial data that showed its lead drug, Sativex, had reduced spasticity in patients with multiple sclerosis.
GW said it would now seek approval from European regulators for the drug. "Given the regulator has seen most of this data before, we feel the approval process should be fairly quick and GW should see the result of its application within six months post filing," Investec Securities said.
Dear Drugs-Forum readers: We are a small non-profit that runs one of the most read drug information & addiction help websites in the world. We serve over 4 million readers per month, and have costs like all popular websites: servers, hosting, licenses and software. To protect our independence we do not run ads. We take no government funds. We run on donations which average $25. If everyone reading this would donate $5 then this fund raiser would be done in an hour. If Drugs-Forum is useful to you, take one minute to keep it online another year by donating whatever you can today. Donations are currently not sufficient to pay our bills and keep the site up. Your help is most welcome. Thank you.